vs
Aardvark Therapeutics, Inc.（AARD）与ABVC BIOPHARMA, INC.（ABVC）财务数据对比。点击上方公司名可切换其他公司
Aardvark Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对炎症、代谢类疾病及罕见病的新型靶向疗法，核心管线聚焦G蛋白偶联受体相关药物，主要服务北美及全球患者群体，开展医药研发领域合作。
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
AARD vs ABVC — 直观对比
营收规模更大
ABVC
是对方的Infinity倍
$0
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $796.0K |
| 净利润 | $-17.6M | $-2.0M |
| 毛利率 | — | 100.0% |
| 营业利润率 | — | -246.8% |
| 净利率 | — | -256.6% |
| 营收同比 | — | 104.5% |
| 净利润同比 | — | -417.4% |
| 每股收益（稀释后） | $-0.81 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AARDABVC
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | $796.0K | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | — | $2.0K | ||
| Q3 24 | — | $389.3K | ||
| Q2 24 | — | $117.1K | ||
| Q1 24 | — | $1.2K |
净利润AARDABVC
| Q4 25 | $-17.6M | — | ||
| Q3 25 | $-16.3M | $-2.0M | ||
| Q2 25 | $-14.4M | — | ||
| Q1 25 | $-9.3M | — | ||
| Q4 24 | — | $-731.6K | ||
| Q3 24 | — | $-394.8K | ||
| Q2 24 | — | $-942.3K | ||
| Q1 24 | — | $-2.8M |
毛利率AARDABVC
| Q4 25 | — | — | ||
| Q3 25 | — | 100.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 100.0% | ||
| Q3 24 | — | 99.9% | ||
| Q2 24 | — | 99.8% | ||
| Q1 24 | — | 77.0% |
营业利润率AARDABVC
| Q4 25 | — | — | ||
| Q3 25 | — | -246.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -35837.4% | ||
| Q3 24 | — | -77.7% | ||
| Q2 24 | — | -734.2% | ||
| Q1 24 | — | -235539.8% |
净利率AARDABVC
| Q4 25 | — | — | ||
| Q3 25 | — | -256.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -37211.3% | ||
| Q3 24 | — | -101.4% | ||
| Q2 24 | — | -804.4% | ||
| Q1 24 | — | -235203.2% |
每股收益（稀释后）AARDABVC
| Q4 25 | $-0.81 | — | ||
| Q3 25 | $-0.75 | $-0.09 | ||
| Q2 25 | $-0.66 | — | ||
| Q1 25 | $-0.71 | — | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.0M | $257.2K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $106.6M | $12.1M |
| 总资产 | $117.2M | $21.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AARDABVC
| Q4 25 | $110.0M | — | ||
| Q3 25 | $126.3M | $257.2K | ||
| Q2 25 | $141.8M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | — | $313.1K | ||
| Q3 24 | — | $208.2K | ||
| Q2 24 | — | $200.0K | ||
| Q1 24 | — | $106.4K |
股东权益AARDABVC
| Q4 25 | $106.6M | — | ||
| Q3 25 | $122.4M | $12.1M | ||
| Q2 25 | $136.9M | — | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $1.7M |
总资产AARDABVC
| Q4 25 | $117.2M | — | ||
| Q3 25 | $133.2M | $21.2M | ||
| Q2 25 | $147.5M | — | ||
| Q1 25 | $157.0M | — | ||
| Q4 24 | — | $7.5M | ||
| Q3 24 | — | $7.8M | ||
| Q2 24 | — | $8.0M | ||
| Q1 24 | — | $8.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.8M | $-964.7K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AARDABVC
| Q4 25 | $-16.8M | — | ||
| Q3 25 | $-16.1M | $-964.7K | ||
| Q2 25 | $-9.8M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | — | $-702.1K | ||
| Q3 24 | — | $60.2K | ||
| Q2 24 | — | $-211.4K | ||
| Q1 24 | — | $-955.8K |
自由现金流AARDABVC
| Q4 25 | — | — | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-9.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
